MDMagdalena Drozyńska-Duklas

Magdalena Drozyńska-Duklas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Magdalena Drozyńska-Duklas has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Successful Treatment of Catastrophic Antiphospholipid Syndrome with Mycophenolate Mofetil in a Teenager Without Underlying Disease

    by Maciej Niedźwiecki, Janusz Springer, Magdalena Drozyńska-Duklas, Piotr Czarniak, Mieszko Czapliński

    Catastrophic antiphospholipid syndrome (CAPS) is a severe form of the antiphospholipid syndrome, a rare autoimmune disease characterized by the presence of antiphospholipid antibodies (APAs) directed against endothelial and plasma proteins in association with recurrent venous and/or arterial thromboembolic events and/or foetal loss. CAPS is marked by small vessel thrombosis, multiorgan failure and a mortality rate of up to 50%. The currently preferred treatment regimen for CAPS includes: anticoagulants, glucocorticosteroids, plasmapheresis with or without intravenous immunoglobulins. Our case of a paediatric CAPS patient is unusual for two reasons: 1) the patient did not suffer from SLE or any other risk factor correlated with increased possibility of thrombosis or CAPS and 2) it is probably the first published case demonstrating successful a remission of CAPS with the immunosuppressant mycophenolate mofetil (MMF) and anti-coagulants. Thus, our case highlights the need for further clinical trials of the effectiveness of new immunosuppressants in the treatment of CAPS and APS.

  • Open Access

    The Outcome of Childhood Immunoglobulin A Nephropathy with Acute Kidney Injury at the Onset of the Disease—National Study

    by M. Mizerska-Wasiak, E. Płatos, J. Małdyk, M. Miklaszewska, D. Drożdż, A. Firszt-Adamczyk, R. Stankiewicz, B. Bieniaś, P. Sikora, A. Rybi-Szumińska, et al.

    Introduction: IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. Decreased glomerular filtration rate is a known risk factor for disease progression. Aim: We aimed to examine factors that may contribute to disease progression in children that present with impaired eGFR at the onset of IgAN. Materials and methods: Of the 175 patients with IgAN from the Polish Registry of Children with IgAN and IgAVN, 54 (31%) patients with IgAN who had an onset of renal function impairment (GFR < 90 mL/min) were eligible for the study. All of them were analyzed for initial symptoms (GFR according to Schwartz formula, creatinine, proteinuria, IgA, C3), renal biopsy result with assessment by Oxford classification, treatment used (R—renoprotection, P—prednisone+R, Aza—azathioprine+P+R, Cyc—cyclophosphamide+P+R, CsA—cyclosporine+P+R, MMF—mycophenolate mofetil+P+R), and distant follow-up. Based on the GFR score obtained at the end, patients were divided into two groups: A—GFR > 90 mL/min and B—GFR < 90 mL/min. Results: In the study group, the mean age of onset was 12.87 ± 3.57 years, GFR was 66.1 ± 17.3 mL/min, and proteinuria was 18.1 (0–967) mg/kg/d. Renal biopsy was performed 0.2 (0–7) years after the onset of the disease, and MESTC score averaged 2.57 ± 1.6. Treatment was R only in 39% of children, P+R in 20%, Aza+P+R in 28%, Cyc+P+R in 9%, CsA+P+R in 7%, and MMF+P+R in 3%. The length of the observation period was 2.16 (0.05–11) years. At the follow-up, Group A had 30 patients (56%) and Group B had 24 patients (44%). There were no significant differences in any of the other biochemical parameters (except creatinine) or proteinuria values between the groups and the frequency of the MESTC score ≥ 2 and p < 0.05) Conclusions: In a population of Polish children with IgAN and decreased renal function at the onset of the disease, 56% had normal GFR in remote observation. The use of immunosuppressive/corticosteroids treatment in children with IgAN and impaired glomerular filtration rate at the beginning of the disease may contribute to the normalization of GFR in the outcome, although this requires confirmation in a larger group of pediatric patients.


  • Open Access

    The Role of Complement Component C3 Activation in the Clinical Presentation and Prognosis of IgA Nephropathy—A National Study in Children

    by Małgorzata Mizerska-Wasiak, Agnieszka Such-Gruchot, Karolina Cichoń-Kawa, Agnieszka Turczyn, Jadwiga Małdyk, Monika Miklaszewska, Dorota Drożdż, Agnieszka Firszt-Adamczyk, Roman Stankiewicz, Agnieszka Rybi-Szumińska, et al.

    The aim of the study was to evaluate the influence of the intensity of mesangial C3 deposits in kidney biopsy and the serum C3 level on the clinical course and outcomes of IgAN in children. The study included 148 children from the Polish Pediatric IgAN Registry, diagnosed based on kidney biopsy. Proteinuria, creatinine, IgA, C3 were evaluated twice in the study group, at baseline and the end of follow-up. Kidney biopsy was categorized using the Oxford classification, with a calculation of the MEST-C score. The intensity of IgA and C3 deposits were rated from 0 to +4 in immunofluorescence microscopy. The intensity of mesangial C3 > +1 deposits in kidney biopsy has an effect on renal survival with normal GFR in children with IgAN. A reduced serum C3 level has not been a prognostic factor in children but perhaps this finding should be confirmed in a larger group of children.